Back to results
US 11,857,530 B2Granted
Cannabinoid formulations
AssigneeEndocanna Health, Inc.
InventorsLen May, Eric Kaufman
Life of this patent
Estimating the term…
Abstract
The disclosure is directed to formulations comprising cannabinoids. More particularly, the cannabinoid formulations can be designed to align with an individual's genotype based on a defined list of polymorphisms.
Claims10
A formulation comprising:
- a cannabidiol (CBD) and a tetrahydrocannabinol (THC), wherein the formulation has a CBD:THC ratio from about 1:1 to about 1:5;
- a primary terpene of myrcene at about 3-5%;
- and
- a secondary terpene of linalool at about 1-5%.
1 more element
Dependencies are inferred from the claim text.